

Claims

1. A transdermal therapeutic system (TTS) for the transcutaneous administration of tolterodine over several days, characterised in that the TTS comprises a self-adhesive matrix material in the form of a layer, which contains a (meth)acrylate copolymer comprising ammonium groups, at least one plasticiser, and up to 25 % by weight tolterodine.
2. A transdermal therapeutic system (TTS) for the transcutaneous administration of tolterodine over several days comprising a means of fixing the TTS to the skin, characterised in that the TTS comprises a self-adhesive matrix material in the form of a layer containing tolterodine, which contains a (meth)acrylate copolymer comprising ammonium groups, at least one plasticiser and up to 25 % by weight tolterodine, and that said matrix material, with the exception of its release surface, is surrounded by a larger patch, which is free from active ingredient, for fixing to the skin at the point of application.
3. A TTS according to claims 1-2, characterised in that the matrix material which contains an active ingredient contains (R,S)-tolterodine or R-tolterodine.
4. A TTS according to claims 1-3, characterised in that the matrix material which contains an active ingredient contains deuterated tolterodine.
5. A TTS according to claims 1-4, characterised in that the matrix material which contains an active ingredient is a solid solution.
6. A TTS according to claims 1-5, characterised in that the matrix material which contains an active ingredient contains at least one triester of citric acid as a plasticiser.
7. A TTS according to claim 6, characterised in that it contains tributyl citrate, on its own or in admixture with triethyl citrate, as a plasticiser.

8. A TTS according to claims 1-7, characterised in that the backing film comprises a metallised or oxide coating on its matrix side.